

KENTUCKY BOARD OF PHARMACY

**Justice and Public Safety Building
125 Holmes Street, 1st Floor Conference Room
Frankfort, KY 40601**

Join Zoom Meeting

<https://us02web.zoom.us/join/register/MFj8e-00SOyfU1iRArF6xA>

(registration with a valid email address is required)

July 15, 2026

9:00 a.m.

Board Meeting Agenda

- I. CALL TO ORDER**
- II. APPEARANCES**
 - A. JADA Foundation
 - B. Partnership for Safe Medicines
- III. APPLICATIONS**
 - A. Pharmacist Reinstatement
 - i. Bonomini, Michael (017266-suspended)
 - B. Resident Pharmacy Facility Amendment
 - i. U of L Health- Ambulatory Pharmacy- University Hospital (P06174)
 - ii. U of L Health- Medical Center East Pharmacy (P08221)
- IV. CORRESPONDENCE**
 - A. Sink Waiver Request
 - i. Baptist Health ER Urgent Care- Georgetown (HOST-EJ1ILL)
 - ii. Rx Therapy Management (P08105)
 - B. Dual PIC Requests
 - i. Gurka, Joseph (022959) for IN3282 & Pending Non-Resident Pharmacy Application (HART-4Q57GD)
 - ii. Collins, Tiffany (017071) for P08208 & CP00142
- V. COMMITTEE REPORTS**
 - A. KYPRN*
 - B. Protocol Review Committee
 - i. Self-Care Conditions Protocol: Emergency Contraception V2
- VI. INTERAGENCY/PROFESSIONAL ASSOCIATIONS**

VII. BOARD REPORTS

- A. Executive Director
 - a. eMars
 - b. Salary Increment Request- Hannah Rodgers
 - c. Policy and Procedure Manual Update
 - d. FDA PCAC proposed comments on bulk substances being considered for inclusion on the 503A Bulks List
 - e. CE Audit Update
- B. General Counsel
 - a. Evidence Collection Policy
 - b. KRS 335B- Predetermination of Licensure Eligibility (for those convicted of a crime)
 - c. Inactive License Jurisdiction Memo

VIII. OLD BUSINESS

- A. Board Retreat Follow-up Items

IX. NEW BUSINESS

- A. 201 KAR 2:160 Proposed Amendment
- B. 201 KAR 2:280 Proposed Amendment

X. CLOSED SESSION DISCUSSION REQUIRED*

- A. Current or Pending Litigation
 - i. 2026 CRP
 - 1. Downing, Lauren (24-0148)

*Material not included in Board Packet

XI. ADJOURNMENT

ATTENTION: A portion of the meeting may be held in closed/executive session for the purpose of discussing and deliberating upon open investigations or the review of information required to be conducted in private according to federal and state law. The specific statutory sections authorizing closed session are KRS 61.810(1)(c) KRS 61.878(1)(a) KRS 61.810(1)(j) KRS 61.878(1)(h) KRS 61.810(1)(k). Following discussion and deliberation, any and all action will be taken in open/public session.

201 KAR 2:160. Licensees; inactive status.

RELATES TO: KRS Chapter 315

STATUTORY AUTHORITY: KRS 315.065, 315.110, 315.120, 315.191(1)

CERTIFICATION STATEMENT: This is to certify that this administrative regulation complies with the requirements of 2025 RS HB 6, Section 8.

NECESSITY, FUNCTION, AND CONFORMITY: KRS 315.191(1) authorizes the board to promulgate administrative regulations to regulate and control all matters set forth in KRS Chapter 315 relating to pharmacists. KRS 315.120(4) authorizes an inactive pharmacist to apply for inactive license upon application provided for by the board in administrative regulations. This administrative regulation establishes requirements for licensees to be issued inactive status and for those who desire to apply for renewal of a license to return to active practice.

Section 1. A pharmacist may apply for inactive status by:

- (1) Completing the annual renewal application, as incorporated by reference in 201 KAR 2:020; and
- (2) Paying the annual fee for inactive status established by 201 KAR 2:050, Section 1(5).

Section 2. Pharmacists ~~maintaining an active license to practice in another state or jurisdiction~~ shall not be eligible **to submit an application** for inactive status in Kentucky **under the following circumstances:**

- (1) The pharmacist maintains an active license to practice in another state or jurisdiction; or**
- (2) The pharmacist is under current investigation by the Board.**

Section 3. Pharmacists seeking relicensure from inactive to active status shall fulfill the following requirements:

- (1) If the pharmacist has been inactive for no more than five (5) consecutive years, the pharmacist shall:
 - (a) Provide written notice to the board requesting their consideration to active status. The board shall act upon the request within sixty (60) days;
 - (b) Satisfy the board's continuing education requirements for each year of inactive status;
 - ~~(c) Successfully complete a jurisprudence examination given by the board; and~~
 - (d) Pay all cumulative annual renewal fees required for active licensees established by 201 KAR 2:050, Section 1(3).**
- (2) If a pharmacist has had inactive status for more than five (5) consecutive years, the pharmacist shall:
 - (a) Provide written notice to the board requesting their consideration to active status. The board shall act upon the request within sixty (60) days;
 - (b) Successfully complete ~~any satisfactory examinations~~ the North American Pharmacist Licensure Examination (NAPLEX) and Multistate Pharmacy Jurisprudence Examination (MPJE) ; and**
 - (c) Pay all cumulative annual renewal fees required of active licensees established by 201 KAR 2:050, Section 1(3).**

(201 KAR 002: 160. 9 Ky.R. 633; 778; eff. 12-1-1982; Crt eff. 4-17-2019; 52 Ky.R. 1171, 1681; eff. 6-16-2026.)

BOARDS AND COMMISSIONS
Board of Pharmacy
(Amendment)

201 KAR 2:280. Prescription dispensing for formulary Compliance.

RELATES TO: KRS 217.822, 315.191

STATUTORY AUTHORITY: KRS 315.191(1)(a), (f)

CERTIFICATION STATEMENT: This is to certify that this administrative regulation complies with the requirements of 2025 RS HB 6, Section 8.

NECESSITY, FUNCTION, AND CONFORMITY: KRS 315.191(1)(a) authorizes the board to promulgate administrative regulations necessary to regulate and control all matters set forth in KRS Chapter 315 relating to pharmacists. KRS 315.191(1)(f) authorizes the board to promulgate administrative regulations to control the storage, retrieval, dispensing, refilling, and transfer of prescription drug orders within and between qualifying pharmacists and pharmacies. This administrative regulation establishes procedural and substantive requirements for dispensing an equivalent drug product pursuant to a practitioner declaration of formulary compliance approval.

Section 1. Dispensing.

(1) A pharmacist may dispense a therapeutic equivalent drug product under the following conditions:

(a) The ordering practitioner has indicated "formulary compliance approval" on the prescription, in one of the following ways:

1. In the practitioner's own handwriting or an equivalent designation within an electronic system; or
2. By checking a "formulary compliance approval" box on a preprinted form; or
3. By indicating a "formulary compliance approval" through a note, prescriber comment or other designation within an electronic prescription system.

(b) The pharmacist receives a formulary change as a consequence of the patient's third-party plan **unless the dispensing is occurring pursuant to legend drug repository program**; and

(c) The product designated as "preferred" by the third-party formulary is in the same therapeutic class as the prescribed drug.

(2) The pharmacist, within twenty-four (24) hours of the formulary compliance substitution, shall notify the ordering practitioner, in an original writing or by facsimile:

- (a) That the pharmacist engaged in formulary compliance; and
- (b) The therapeutic equivalent drug product that was dispensed.

Section 2. The pharmacist may make adjustments in the quantity and directions to provide for an equivalent dose of the preferred formulary therapeutic alternative.